151 related articles for article (PubMed ID: 18085616)
1. Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent.
Makarov DV; Marlow C; Epstein JI; Miller MC; Landis P; Partin AW; Carter HB; Veltri RW
Prostate; 2008 Feb; 68(2):183-9. PubMed ID: 18085616
[TBL] [Abstract][Full Text] [Related]
2. Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry.
Veltri RW; Miller MC; Isharwal S; Marlow C; Makarov DV; Partin AW
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):102-10. PubMed ID: 18199716
[TBL] [Abstract][Full Text] [Related]
3. Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy.
Khan MA; Walsh PC; Miller MC; Bales WD; Epstein JI; Mangold LA; Partin AW; Veltri RW
Cancer; 2003 Dec; 98(12):2583-91. PubMed ID: 14669277
[TBL] [Abstract][Full Text] [Related]
4. Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei.
Veltri RW; Miller MC; Partin AW; Coffey DS; Epstein JI
Urology; 1996 Nov; 48(5):685-91. PubMed ID: 8911509
[TBL] [Abstract][Full Text] [Related]
5. Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate.
Veltri RW; Khan MA; Miller MC; Epstein JI; Mangold LA; Walsh PC; Partin AW
Clin Cancer Res; 2004 May; 10(10):3465-73. PubMed ID: 15161703
[TBL] [Abstract][Full Text] [Related]
6. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?
Khan MA; Carter HB; Epstein JI; Miller MC; Landis P; Walsh PW; Partin AW; Veltri RW
J Urol; 2003 Dec; 170(6 Pt 1):2274-8. PubMed ID: 14634395
[TBL] [Abstract][Full Text] [Related]
7. Value of computer-assisted quantitative nuclear grading in differentiation of normal urothelial cells from low and high grade transitional cell carcinoma.
Wojcik EM; Miller MC; O'Dowd GJ; Veltri RW
Anal Quant Cytol Histol; 1998 Feb; 20(1):69-76. PubMed ID: 9513693
[TBL] [Abstract][Full Text] [Related]
8. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
[TBL] [Abstract][Full Text] [Related]
9. Standardization, analytical validation, and quality control of intermediate endpoint biomarkers.
Veltri RW; Miller MC; An G
Urology; 2001 Apr; 57(4 Suppl 1):164-70. PubMed ID: 11295618
[TBL] [Abstract][Full Text] [Related]
10. Quantitative nuclear grade (QNG): a new image analysis-based biomarker of clinically relevant nuclear structure alterations.
Veltri RW; Partin AW; Miller MC
J Cell Biochem Suppl; 2000; Suppl 35():151-7. PubMed ID: 11389545
[TBL] [Abstract][Full Text] [Related]
11. DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction.
Isharwal S; Miller MC; Epstein JI; Mangold LA; Humphreys E; Partin AW; Veltri RW
Urology; 2009 May; 73(5):1092-7. PubMed ID: 19193410
[TBL] [Abstract][Full Text] [Related]
12. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
14. Nuclear Shape and Architecture in Benign Fields Predict Biochemical Recurrence in Prostate Cancer Patients Following Radical Prostatectomy: Preliminary Findings.
Lee G; Veltri RW; Zhu G; Ali S; Epstein JI; Madabhushi A
Eur Urol Focus; 2017 Oct; 3(4-5):457-466. PubMed ID: 28753763
[TBL] [Abstract][Full Text] [Related]
15. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
16. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy.
Potter SR; Miller MC; Mangold LA; Jones KA; Epstein JI; Veltri RW; Partin AW
Urology; 1999 Nov; 54(5):791-5. PubMed ID: 10565735
[TBL] [Abstract][Full Text] [Related]
17. Alterations in nuclear structure and expression of proPSA predict differences between native Japanese and Japanese-American prostate cancer.
Veltri RW; Khan MA; Marlow C; Miller MC; Mikolajczyk SD; Kojima M; Partin AW; Marks LS
Urology; 2006 Oct; 68(4):898-904. PubMed ID: 17070389
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
[TBL] [Abstract][Full Text] [Related]
19. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.
Carter HB; Walsh PC; Landis P; Epstein JI
J Urol; 2002 Mar; 167(3):1231-4. PubMed ID: 11832703
[TBL] [Abstract][Full Text] [Related]
20. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression.
Veltri RW; Partin AW; Epstein JE; Marley GM; Miller CM; Singer DS; Patton KP; Criley SR; Coffey DS
J Cell Biochem Suppl; 1994; 19():249-58. PubMed ID: 7529856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
